Product Overview

Harnessing the Healing Power of Nature

Despite advances in wound care, patients still suffer from recalcitrant wounds. Burns, pressure ulcers, chronic venous ulcers, and diabetic ulcers continue to place a heavy burden on patients as well as the health care system. There is clearly an unmet need for more efficient and effective wound care interventions.1

Molecular Biologicals has developed 3 advanced wound healing products that deliver pharmaceutical-grade Replicine™ Bioactive Keratin to the wound bed, facilitating a moist wound-healing environment and effectively managing wound exudates. All 3 products offer clinical and therapeutic benefits, including:

  • Increasing the rates of proliferation and migration of keratinocyte cells to jumpstart the healing process1,2
  • Accelerating epithelialization and wound closure1,3
  • Stimulating critical collagens (IV and VII) for wound healing4
  • Providing an optimum healing environment while promoting tissue healing4
  • First-line therapy option for acute first- and second-degree burns, as well as sunburns5-7
  • Improved benefits for surgical wounds, cuts, or abrasions5-7

Keragel® and KeragelT® are hydrogels enriched with pharmaceutical-grade keratin protein designed for dry or low exudates wounds and skin disorders.5,6

Keramatrix® is an absorbable matrix enriched with pharmaceutical-grade keratin protein.7



A thicker gel that has superior exudates handling.


A thinner gel that is faster drying, ideal for patients with Epidermolysis Bullosa.


An absorbable matrix enriched with pharmaceutical-grade keratin protein.

Clinical efficacy with Molecular Biological’s Keratin products has been demonstrated in:

  • Venous stasis ulcers2,8-10
  • Arterial ulcers2,8-10
  • Diabetic foot ulcers3
  • Pressure ulcers2,8-10
  • Vascular ulcers of mixed etiology2,8-10
  • Skin graft donor sites11
  • First and second degree burns and sunburns12
  • Skin tears13
  • Superficial injuries, cuts, abrasions, and surgical wounds13
  • Acute Surgical Wounds13
  • Chronic wounds2,8-10
  • Improving skin conditions and wounds caused by Epidermolysis Bullosa (EB)14-17

View our Clinical Data

CONTRAINDICATIONS: Keramatrix® should not be used in patients with known sensitivity to keratin or any of the excipients.


1.Pechter PM, Gil J, Valdes J, et al. Keratin dressings speed epithelialization of deep partial-thickness wounds. Wound Rep Reg. 2012;20:236-242. 2. Batzer AT, Marsh C, Kirsner RS. The use of keratin-based wound products on refractory wounds. Int Wound J. 2016;13(1):110-115. 3. Walid F, Patel SR, Wu S. A new approach to diabetic foot ulcers using keratin gel technology. Presented at: Center for Lower Extremity Ambulatory Research; North Chicago, IL; 1-25. 4. Tang L, Sierra JO, Kelly R, et al. Wool-derived keratin stimulates human keratinocyte migration and types IV and VII collagen expression. Exper Derm. 2012(21):456-476. 5. Keragel® [package insert.] Molecular Biologicals: Pasadena, TX; 2017. 6. KeragelT® [package insert.] Molecular Biologicals: Pasadena, TX; 2017. 7. Keramatrix® [package insert.] Molecular Biologicals: Pasadena, TX; 2017. 8. Than MP, Smith RA, Kirsner RS. Keratin-based wound care products for treatment of resistant vascular wounds. J Clin Aest Derm. 2012;5(12):31-35. 9. Hammond CE, Than M, Walker JW. From the laboratory to the leg: Patients’ and nurses’ perceptions of product application using three different dressing formats. Wound Prac Res. 2010;18(4);189-195. 10.Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers will heal with limb compression bandages? Am J Med. 2000;109:15-19. 11. Davidson A, Jina NH, Marsh C, et al. Do functional keratin dressings accelerate epithelialization in human partial thickness wounds? A randomized controlled trial on skin graft donor sites. Eplasty. 2013;3:375-381. 12. Loan F, Cassidy S, Marsh C, et al. Keratin-based products for effective wound care management in superficial and partial thickness burns injuries. Science Direct. 201;42:541-547. 13. Jina NH, Marsh C, Than M, et al. Keratin gel improves poor scarring following median sternotomy. ANZ J Surg. 2015;85(5):378-380. 14. Tadini G, Marsh C, Kirsner R. An evaluation of a keratin gel to accelerate healing and  improve care for epidermolysis bullosa patients. Poster presented at: Symposium on Advanced Wound Care, San Antonio, TX; April 2015. 15. Denyer J, Marsh C, Kirsner RS. Keratin gel in the management of Epidermolysis bullosa. J Wound Care. 2015;24(10):446-450. 16. Kirsner RS, Cassidy S, Marsh C, et al. Use of a keratin-based wound dressing in the management of wounds in a patient with recessive dystrophic epidermolysis bullosa. Adv Skin Wound Care. 2012;25(9):400-403. 17. Than MP, Smith RA, Cassidy S, et al. Use of a keratin-based hydrogel in the management of recessive dystrophic epidermolysis bullosa. J Derm Treat. 2012:1-2.